# A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

> **NCT01744665** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- CML

## Interventions

- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT01744665
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-12
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-09-29
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744665, "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01744665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*